Canada markets closed

Celyad Oncology SA (CLYYF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.35800.0000 (0.00%)
At close: 09:30AM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 13.69M
Enterprise Value 8.93M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)171.26
Price/Book (mrq)13.58
Enterprise Value/Revenue 202.89
Enterprise Value/EBITDA -0.29

Trading Information

Stock Price History

Beta (5Y Monthly) 1.30
52-Week Change 3-92.30%
S&P500 52-Week Change 322.38%
52 Week High 34.6500
52 Week Low 30.3580
50-Day Moving Average 30.3795
200-Day Moving Average 30.5013

Share Statistics

Avg Vol (3 month) 354
Avg Vol (10 day) 3N/A
Shares Outstanding 541.43M
Implied Shares Outstanding 641.59M
Float 811.86M
% Held by Insiders 17.63%
% Held by Institutions 135.50%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in EUR.

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-8,110.35%

Management Effectiveness

Return on Assets (ttm)-33.03%
Return on Equity (ttm)-159.08%

Income Statement

Revenue (ttm)102k
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -9M
Net Income Avi to Common (ttm)-8.45M
Diluted EPS (ttm)-1.4600
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)7M
Total Cash Per Share (mrq)0.17
Total Debt (mrq)1.06M
Total Debt/Equity (mrq)16.78%
Current Ratio (mrq)3.79
Book Value Per Share (mrq)0.15

Cash Flow Statement

Operating Cash Flow (ttm)-15.2M
Levered Free Cash Flow (ttm)-14.45M